Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

I just wanted to take this opportunity to thank you for all your support throughout my interview process with the client.
Annie, 2012

Shire sells off ADHD treatment to Noven

11 August 2010 00:00 in Pharmaceutical Company Product News

Shire has announced the sale of the attention deficit hyperactivity disorder (ADHD) therapy Daytrana to Noven Pharmaceuticals, the drug's original developer.

The treatment, which is specified for use among children and adolescents, has been sold by Shire since being licensed from manufacturer Noven in 2003.

Following the commencement of the new arrangement, which is due to take effect on October 1st 2010, global marketing rights for the drug will be returned to Noven.

Shire estimates the value of the divested assets at around $95 million (60.2 million pounds), but stated that the move will not affect its recently-announced earnings outlook for the 2010 full-year period.

Earlier this week, Shire published data from a new phase IIIb clinical trial of another ADHD therapy Vyvanse, in order to demonstrate its efficacy among adult patients.

It is hoped that the treatment can now be used to help older sufferers of the condition who wish to manage their symptoms during the working day.ADNFCR-8000103-ID-800020557-ADNFCR

Other news stories from 11/08/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd